We can’t show the full text here under this license. Use the link below to read it at the source.
Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
Tirzepatide, a drug targeting two hormone receptors, may improve insulin-producing cell function and insulin sensitivity in type 2 diabetes
AI simplified
Abstract
Tirzepatide improved markers of insulin sensitivity and beta-cell function more than dulaglutide in 316 subjects with type 2 diabetes.
- Homeostatic model assessment (HOMA) 2-B increased significantly with tirzepatide at doses of 5, 10, and 15 mg compared to placebo.
- Proinsulin/insulin and proinsulin/C-peptide ratios decreased significantly with tirzepatide at 10 and 15 mg compared to both placebo and dulaglutide.
- Fasting insulin levels significantly decreased with tirzepatide at 10 and 15 mg compared to placebo and dulaglutide.
- Improvements in insulin sensitivity markers such as adiponectin and IGFBP-1 were observed with tirzepatide at one or more doses.
- Weight loss explained only 13% and 21% of the improvement in insulin resistance markers (HOMA2-IR) with tirzepatide at 10 and 15 mg, respectively.
AI simplified
Key numbers
93% to 163%
Increase in HOMA2-B Indices
Percent change from baseline for tirzepatide doses at 26 weeks.
P ≤ .033
Decrease in Fasting Insulin Levels
Statistical significance for fasting insulin levels with tirzepatide 10 and 15 mg.
13% to 21%
Weight Loss Contribution
Percentage of improvement in HOMA2-IR explained by weight loss with tirzepatide.